Boston Scientific's REBEL coronary stent system receives CE mark13 March 2014 Boston Scientific Corporation has received EU approval for its REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD). The REBEL Stent System offers the same stent platform as the Promus PREMIER drug eluting stent (DES) but without the Everolimus drug. Bare metal stents continue to play an important role in the treatment of coronary artery disease and represent a significant portion of the global stent market. "I am glad to have a bare metal stent that performs like the PREMIER DES but allows me to treat patients who are not candidates for DES therapy," said Prof. Didier Carrie, M.D., Ph.D., an investigator for the OMEGA clinical trial at Centre Hopital Universitaire, Rangueil, France. "In addition to its great visibility and deliverability, the platinum chromium stent architecture features low recoil that is particularly important for patients treated with bare metal stents." The REBEL Stent System features unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability. Its enhanced low-profile delivery system also features a shorter, more visible tip, a dual-layer balloon and a Bi-Segment™ inner lumen catheter designed to facilitate precise stent delivery across challenging lesions. CAD is a narrowing of blood vessels that supply blood and oxygen to the heart. Patients with CAD may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. A primary treatment for CAD is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.
|
|||